{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:37:11Z","timestamp":1792931831236,"version":"4.5.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01764-2","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T23:01:08Z","timestamp":1750719668000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7613","authenticated-orcid":false,"given":"Hamed","family":"Soleimani Samarkhazan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9755-2850","authenticated-orcid":false,"given":"Hanieh","family":"Noormohamadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7769-8320","authenticated-orcid":false,"given":"Fatemeh Sadat","family":"Shafiei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-6092","authenticated-orcid":false,"given":"Zahra","family":"Taghinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4559-6525","authenticated-orcid":false,"given":"Mohsen","family":"Maleknia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1029-751X","authenticated-orcid":false,"given":"Atieh","family":"Raoufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4863-2595","authenticated-orcid":false,"given":"Sina","family":"Nouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4884-5218","authenticated-orcid":false,"given":"Mohammad Hossein","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"1764_CR1","volume":"171","author":"Y Wu","year":"2024","unstructured":"Wu Y, et al. Immunotherapies of acute myeloid leukemia: rationale, clinical evidence and perspective. Biomed Pharmacother. 2024;171: 116132.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"1764_CR2","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.3390\/cancers13092256","volume":"13","author":"CK Tebbi","year":"2021","unstructured":"Tebbi CK. Etiology of acute leukemia: a review. Cancers. 2021;13(9):2256.","journal-title":"Cancers"},{"key":"1764_CR3","first-page":"1","volume-title":"Acute Myeloid Leukemia","author":"G Juliusson","year":"2021","unstructured":"Juliusson G, Lehmann S, Lazarevic V. Epidemiology and Etiology of AML. In: R\u00f6llig C, Ossenkoppele GJ, editors. Acute Myeloid Leukemia. Cham: Springer International Publishing; 2021. p. 1\u201322."},{"issue":"4","key":"1764_CR4","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3390\/cancers13040748","volume":"13","author":"H Pasquer","year":"2021","unstructured":"Pasquer H, et al. Descriptive and functional genomics in acute myeloid leukemia (AML): paving the road for a cure. Cancers. 2021;13(4):748.","journal-title":"Cancers"},{"key":"1764_CR5","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101821","volume":"39","author":"HQ Sadida","year":"2024","unstructured":"Sadida HQ, et al. Epigenetic modifications: key players in cancer heterogeneity and drug resistance. Transl Oncol. 2024;39: 101821.","journal-title":"Transl Oncol"},{"issue":"4","key":"1764_CR6","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1172\/JCI129204","volume":"130","author":"L Vago","year":"2020","unstructured":"Vago L, Gojo I. Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest. 2020;130(4):1552\u201364.","journal-title":"J Clin Invest"},{"issue":"4","key":"1764_CR7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"},{"issue":"4","key":"1764_CR8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41409-018-0286-2","volume":"54","author":"CJ Lee","year":"2019","unstructured":"Lee CJ, et al. Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the acute leukemia working party of the European society for blood and marrow transplantation. Bone Marrow Transplant. 2019;54(4):519\u201330.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"1764_CR9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"21","key":"1764_CR10","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144(21):2169\u201373.","journal-title":"Blood"},{"issue":"4","key":"1764_CR11","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","volume":"8","author":"A Bataller","year":"2024","unstructured":"Bataller A, et al. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv. 2024;8(4):927\u201335.","journal-title":"Blood Adv"},{"issue":"1","key":"1764_CR12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40364-024-00649-y","volume":"12","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, et al. Global, regional, and national burden of acute myeloid leukemia, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Biomark Res. 2024;12(1):101.","journal-title":"Biomark Res"},{"issue":"24","key":"1764_CR13","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.3390\/cancers13246246","volume":"13","author":"A Aureli","year":"2021","unstructured":"Aureli A, et al. Immunotherapy as a turning point in the treatment of acute myeloid leukemia. Cancers. 2021;13(24):6246.","journal-title":"Cancers"},{"key":"1764_CR14","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/GO.20.00660","volume":"7","author":"B Alahmari","year":"2021","unstructured":"Alahmari B, et al. Management approach to acute myeloid leukemia leveraging the available resources in view of the latest evidence: consensus of the Saudi society of blood and marrow transplantation. JCO Glob Oncol. 2021;7:1220\u201332.","journal-title":"JCO Glob Oncol"},{"issue":"3","key":"1764_CR15","first-page":"28","volume":"11","author":"A Noroozi Aghide","year":"2016","unstructured":"Noroozi Aghide A, Soleimani Samarkhazan H, Ahmadnezhad M. Effect of harmine alkaloid on the expression of P16 and DAPK in HL60 leukemia cell line. Paramed Sci Milit Health. 2016;11(3):28\u201333.","journal-title":"Paramed Sci Milit Health"},{"issue":"3","key":"1764_CR16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/bmt.2016.308","volume":"52","author":"F Buccisano","year":"2017","unstructured":"Buccisano F, et al. Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia. Bone Marrow Transplant. 2017;52(3):473\u20135.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"1764_CR17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40364-025-00786-y","volume":"13","author":"S Zehtabcheh","year":"2025","unstructured":"Zehtabcheh S, et al. Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies. Biomark Res. 2025;13(1):73.","journal-title":"Biomark Res"},{"issue":"1","key":"1764_CR18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13287-022-02829-9","volume":"13","author":"H Dianat-Moghadam","year":"2022","unstructured":"Dianat-Moghadam H, et al. Immune evader cancer stem cells direct the perspective approaches to cancer immunotherapy. Stem Cell Res Ther. 2022;13(1):150.","journal-title":"Stem Cell Res Ther"},{"key":"1764_CR19","doi-asserted-by":"crossref","first-page":"1151032","DOI":"10.3389\/fphar.2023.1151032","volume":"14","author":"Y Chen","year":"2023","unstructured":"Chen Y, et al. A perspective of immunotherapy for acute myeloid leukemia: current advances and challenges. Front Pharmacol. 2023;14:1151032.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1764_CR20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12032-025-02742-0","volume":"42","author":"MJ Saadh","year":"2025","unstructured":"Saadh MJ, et al. Mesenchymal stem cell-derived exosomes: a novel therapeutic frontier in hematological disorders. Med Oncol. 2025;42(6):199.","journal-title":"Med Oncol"},{"issue":"6","key":"1764_CR21","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.3390\/ijms23063304","volume":"23","author":"J Greiner","year":"2022","unstructured":"Greiner J, G\u00f6tz M, Wais V. Increasing role of targeted immunotherapies in the treatment of AML. Int J Mol Sci. 2022;23(6):3304.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1764_CR22","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1007\/s00277-024-06117-9","volume":"103","author":"C Zha","year":"2024","unstructured":"Zha C, et al. Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies. Ann Hematol. 2024;103(12):4883\u201399.","journal-title":"Ann Hematol"},{"issue":"Supplement 1","key":"1764_CR23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2024-211845","volume":"144","author":"E Ayoub","year":"2024","unstructured":"Ayoub E, et al. Single-cell multiomics unveils venetoclax-resistant monocytic differentiation and immune evasion in TP53 mutant AML clones. Blood. 2024;144(Supplement 1):61\u201361.","journal-title":"Blood"},{"key":"1764_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02566-x","author":"C Reinhardt","year":"2025","unstructured":"Reinhardt C, Ochsenbein AF. Immune checkpoints regulate acute myeloid leukemia stem cells. Leukemia. 2025. https:\/\/doi.org\/10.1038\/s41375-025-02566-x.","journal-title":"Leukemia"},{"key":"1764_CR25","doi-asserted-by":"crossref","first-page":"1151032","DOI":"10.3389\/fphar.2023.1151032","volume":"14","author":"Y Chen","year":"2023","unstructured":"Chen Y, Wang J, Zhang F, Liu P. A perspective of immunotherapy for acute myeloid leukemia: current advances and challenges. Front Pharmacol. 2023;14:1151032.","journal-title":"Front Pharmacol"},{"key":"1764_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06387-x","author":"OS Aval","year":"2025","unstructured":"Aval OS, et al. Galectin-9: a double-edged sword in acute myeloid leukemia. Ann Hematol. 2025. https:\/\/doi.org\/10.1007\/s00277-025-06387-x.","journal-title":"Ann Hematol"},{"key":"1764_CR27","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104743","volume":"211","author":"M Chatterjee","year":"2025","unstructured":"Chatterjee M, et al. Extracellular vesicles in acute myeloid leukemia: the role in disease pathogenesis, potential biomarker, and application in clinical settings. Crit Rev Oncol Hematol. 2025;211: 104743.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1764_CR28","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/hematology.2023000455","volume":"2023","author":"M Subklewe","year":"2023","unstructured":"Subklewe M, et al. Novel immunotherapies in the treatment of AML: is there hope? Hematology. 2023;2023(1):691\u2013701.","journal-title":"Hematology"},{"issue":"1","key":"1764_CR29","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1186\/s12967-023-04579-5","volume":"21","author":"X Wu","year":"2023","unstructured":"Wu X, et al. Spatiotemporal evolution of AML immune microenvironment remodeling and RNF149-driven drug resistance through single-cell multidimensional analysis. J Transl Med. 2023;21(1):760.","journal-title":"J Transl Med"},{"issue":"13","key":"1764_CR30","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2024025706","volume":"145","author":"C Rothfu\u00df","year":"2025","unstructured":"Rothfu\u00df C, et al. Two-layered immune escape in AML is overcome by Fc\u03b3 receptor activation and inhibition of PGE2 signaling in NK cells. Blood. 2025;145(13):1395\u2013406.","journal-title":"Blood"},{"issue":"3","key":"1764_CR31","doi-asserted-by":"crossref","first-page":"674","DOI":"10.20517\/cdr.2023.39","volume":"6","author":"G Lindsay","year":"2023","unstructured":"Lindsay G, Kira G. Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia. Cancer Drug Resist. 2023;6(3):674\u201387.","journal-title":"Cancer Drug Resist"},{"key":"1764_CR32","unstructured":"Borthakur, G., FLAG REGIMEN, COMBINED WITH GEMTUZUMAB (FLAG-GO) Results in better optimal molecular response and outcomes, compared to combination with idarubicin (flag-IDA) in untreated core binding factor aml. EHA library, 2024."},{"issue":"26","key":"1764_CR33","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2014-08-596403","volume":"125","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, et al. Monoclonal antibodies in acute lymphoblastic leukemia. Blood. 2015;125(26):4010\u20136.","journal-title":"Blood"},{"key":"1764_CR34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.biopha.2017.10.100","volume":"97","author":"DO Acheampong","year":"2018","unstructured":"Acheampong DO, et al. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy. Biomed Pharmacother. 2018;97:225\u201332.","journal-title":"Biomed Pharmacother"},{"key":"1764_CR35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01936","volume":"8","author":"C Cuesta-Mateos","year":"2018","unstructured":"Cuesta-Mateos C, et al. Monoclonal antibody therapies for hematological malignancies: not just lineage-specific targets. Front Immunol. 2018;8: 1936.","journal-title":"Front Immunol"},{"issue":"12","key":"1764_CR36","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1080\/14712598.2016.1235148","volume":"16","author":"Y Wu","year":"2016","unstructured":"Wu Y, Jiang S, Ying T. From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain. Expert Opin Biol Ther. 2016;16(12):1469\u201378.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"1764_CR37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.beha.2019.05.002","volume":"32","author":"LM Morsink","year":"2019","unstructured":"Morsink LM, Walter RB. Novel monoclonal antibody-based therapies for acute myeloid leukemia. Best Pract Res Clin Haematol. 2019;32(2):116\u201326.","journal-title":"Best Pract Res Clin Haematol"},{"key":"1764_CR38","doi-asserted-by":"crossref","unstructured":"Masarova, L., et al., Update on immunotherapy in AML and MDS: monoclonal antibodies and checkpoint inhibitors paving the road for clinical practice. Immunotherapy, 2018: p. 97\u2013116.","DOI":"10.1007\/978-3-030-02505-2_4"},{"issue":"1","key":"1764_CR39","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s11033-025-10527-x","volume":"52","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. C-type lectin-like molecule-1 as a diagnostic, prognostic, and therapeutic marker in leukemia. Mol Biol Rep. 2025;52(1):464.","journal-title":"Mol Biol Rep"},{"issue":"3","key":"1764_CR40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/antib9030034","volume":"9","author":"D Zahavi","year":"2020","unstructured":"Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies. 2020;9(3):34.","journal-title":"Antibodies"},{"issue":"4","key":"1764_CR41","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","volume":"12","author":"AM Scott","year":"2012","unstructured":"Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278\u201387.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1764_CR42","first-page":"20","volume":"11","author":"PM Glassman","year":"2014","unstructured":"Glassman PM, Balthasar JP. Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biol Med. 2014;11(1):20.","journal-title":"Cancer Biol Med"},{"issue":"18","key":"1764_CR43","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","volume":"23","author":"EJ Feldman","year":"2005","unstructured":"Feldman EJ, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005;23(18):4110\u20136.","journal-title":"J Clin Oncol"},{"issue":"50","key":"1764_CR44","doi-asserted-by":"crossref","first-page":"86987","DOI":"10.18632\/oncotarget.18115","volume":"8","author":"S Sandri","year":"2017","unstructured":"Sandri S, et al. Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. Oncotarget. 2017;8(50):86987.","journal-title":"Oncotarget"},{"key":"1764_CR45","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719860645","volume":"10","author":"ES Winer","year":"2019","unstructured":"Winer ES, Stone RM. Novel therapy in acute myeloid leukemia (AML): moving toward targeted approaches. Ther Adv Hematol. 2019;10: 2040620719860645.","journal-title":"Ther Adv Hematol"},{"issue":"9825","key":"1764_CR46","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508\u201316.","journal-title":"Lancet"},{"issue":"5","key":"1764_CR47","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.clml.2018.02.017","volume":"18","author":"BC Medeiros","year":"2018","unstructured":"Medeiros BC, et al. A phase I\/II trial of the combination of azacitidine and gemtuzumab ozogamicin for treatment of relapsed acute myeloid leukemia. Clin Lymphoma Myeloma Leukemia. 2018;18(5):346\u201352.","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"9","key":"1764_CR48","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","volume":"23","author":"DA Breems","year":"2005","unstructured":"Breems DA, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23(9):1969\u201378.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1764_CR49","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/cancers16020334","volume":"16","author":"M Harfmann","year":"2024","unstructured":"Harfmann M, et al. CD45-directed CAR-T cells with CD45 knockout efficiently kill myeloid leukemia and lymphoma cells in vitro even after extended culture. Cancers. 2024;16(2):334.","journal-title":"Cancers"},{"issue":"1","key":"1764_CR50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00277-023-05520-y","volume":"103","author":"MAS Al Barashdi","year":"2024","unstructured":"Al Barashdi MAS, et al. CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy. Ann Hematol. 2024;103(1):73\u201388.","journal-title":"Ann Hematol"},{"issue":"1","key":"1764_CR51","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11033-024-10200-9","volume":"52","author":"L Rajabi","year":"2025","unstructured":"Rajabi L, et al. Aqueous and ethanolic extracts of Moringa oleifera leaves induce selective cytotoxicity in Raji and Jurkat cell lines by activating the P21 pathway independent of P53. Mol Biol Rep. 2025;52(1):102.","journal-title":"Mol Biol Rep"},{"key":"1764_CR52","doi-asserted-by":"publisher","DOI":"10.1080\/08982104.2025.2495261","author":"A Kubaev","year":"2025","unstructured":"Kubaev A, et al. Platelet-derived extracellular vesicles: emerging players in hemostasis and thrombosis. J Liposome Res. 2025. https:\/\/doi.org\/10.1080\/08982104.2025.2495261.","journal-title":"J Liposome Res"},{"key":"1764_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147542","author":"M Gallazzi","year":"2022","unstructured":"Gallazzi M, et al. New frontiers in monoclonal antibodies for the targeted therapy of acute myeloid leukemia and myelodysplastic syndromes. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23147542.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1764_CR54","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3324\/haematol.2019.229492","volume":"105","author":"P Vo","year":"2020","unstructured":"Vo P, et al. Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed\/refractory leukemia or myelodysplasia. Haematologica. 2020;105(6):1731.","journal-title":"Haematologica"},{"key":"1764_CR55","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2018-99-111914","volume":"132","author":"E Agura","year":"2018","unstructured":"Agura E, et al. Targeted conditioning of Iomab-B (131I-anti-CD45) prior to allogeneic hematopoietic cell transplantation versus conventional care in relapsed or refractory acute myeloid leukemia (AML): preliminary feasibility and safety results from the prospective, randomized phase 3 Sierra trial. Blood. 2018;132:1017.","journal-title":"Blood"},{"key":"1764_CR56","volume":"13","author":"R Maute","year":"2022","unstructured":"Maute R, Xu J, Weissman I. CD47\u2013SIRP\u03b1-targeted therapeutics: status and prospects. Immuno-Oncol Technol. 2022;13: 100070.","journal-title":"Immuno-Oncol Technol"},{"issue":"12","key":"1764_CR57","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.3324\/haematol.2023.283154","volume":"108","author":"A Marra","year":"2023","unstructured":"Marra A, et al. CD47 expression in acute myeloid leukemia varies according to genotype. Haematologica. 2023;108(12):3491.","journal-title":"Haematologica"},{"issue":"3","key":"1764_CR58","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00277-021-04734-2","volume":"101","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM, et al. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Ann Hematol. 2022;101(3):557\u201369.","journal-title":"Ann Hematol"},{"key":"1764_CR59","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1182\/blood-2019-125363","volume":"134","author":"AM Zeidan","year":"2019","unstructured":"Zeidan AM, et al. A phase I study of CC-90002, a monoclonal antibody targeting CD47, in patients with relapsed and\/or refractory (R\/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS): final results. Blood. 2019;134:1320.","journal-title":"Blood"},{"issue":"31","key":"1764_CR60","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","volume":"41","author":"NG Daver","year":"2023","unstructured":"Daver NG, et al. Tolerability and efficacy of the anticluster of differentiation 47 antibody Magrolimab combined with Azacitidine in patients with previously untreated AML: phase Ib results. J Clin Oncol. 2023;41(31):4893\u2013904.","journal-title":"J Clin Oncol"},{"key":"1764_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005517","author":"T Qu","year":"2022","unstructured":"Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-005517.","journal-title":"J Immunother Cancer"},{"key":"1764_CR62","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1182\/blood-2023-180618","volume":"142","author":"H Wang","year":"2023","unstructured":"Wang H, et al. A phase 1b study evaluating the safety and efficacy of ak117 (anti-CD47 monoclonal antibody) in combination with azacitidine in patients with treatment-na\u00efve acute myeloid leukemia. Blood. 2023;142:4280.","journal-title":"Blood"},{"issue":"1","key":"1764_CR63","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10238-025-01588-0","volume":"25","author":"A Raoufi","year":"2025","unstructured":"Raoufi A, et al. Macrophages in graft-versus-host disease (GVHD): dual roles as therapeutic tools and targets. Clin Exp Med. 2025;25(1):73.","journal-title":"Clin Exp Med"},{"issue":"7","key":"1764_CR64","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1007\/s00262-023-03422-6","volume":"72","author":"J Cheng","year":"2023","unstructured":"Cheng J, et al. Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia. Cancer Immunol Immunother. 2023;72(7):2331\u201346.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"1764_CR65","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20152008","volume":"214","author":"C Riether","year":"2017","unstructured":"Riether C, et al. CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. J Exp Med. 2017;214(2):359\u201380.","journal-title":"J Exp Med"},{"key":"1764_CR66","volume-title":"ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade","author":"K Silence","year":"2014","unstructured":"Silence K, et al. ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade. Taylor & Francis; 2014."},{"issue":"21","key":"1764_CR67","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1158\/1078-0432.CCR-17-0613","volume":"23","author":"P Aftimos","year":"2017","unstructured":"Aftimos P, et al. Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies. Clin Cancer Res. 2017;23(21):6411\u201320.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1764_CR68","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","volume":"26","author":"C Riether","year":"2020","unstructured":"Riether C, et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020;26(9):1459\u201367.","journal-title":"Nat Med"},{"key":"1764_CR69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS7565","author":"GC Trudel","year":"2020","unstructured":"Trudel GC, et al. Culminate: a phase II study of cusatuzumab+ azacitidine in patients with newly diagnosed AML, ineligible for intensive chemotherapy. J Clin Oncol. 2020. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS7565.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1764_CR70","doi-asserted-by":"crossref","first-page":"101220","DOI":"10.1016\/j.beha.2020.101220","volume":"33","author":"AG Koshy","year":"2020","unstructured":"Koshy AG, Daver NG, Fathi AT. A new era of immuno-oncology in acute myeloid leukemia-antibody-based therapies and immune checkpoint inhibition. Best Pract Res Clin Haematol. 2020;33(4):101220.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"8","key":"1764_CR71","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","volume":"2","author":"Y Kovtun","year":"2018","unstructured":"Kovtun Y, et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv. 2018;2(8):848\u201358.","journal-title":"Blood Adv"},{"issue":"17","key":"1764_CR72","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-14-3186","volume":"21","author":"DF Angelini","year":"2015","unstructured":"Angelini DF, et al. A leukemia-associated CD34\/CD123\/CD25\/CD99+ immunophenotype identifies FLT3-mutated clones in acute myeloid leukemia. Clin Cancer Res. 2015;21(17):3977\u201385.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1764_CR73","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.3390\/ijms24032718","volume":"24","author":"E Pelosi","year":"2023","unstructured":"Pelosi E, Castelli G, Testa U. CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm. Int J Molecular Sci. 2023;24(3):2718.","journal-title":"Int J Molecular Sci"},{"issue":"4","key":"1764_CR74","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/s41375-019-0645-z","volume":"34","author":"AS Kubasch","year":"2020","unstructured":"Kubasch AS, et al. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia. 2020;34(4):1182\u20136.","journal-title":"Leukemia"},{"issue":"1","key":"1764_CR75","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41375-020-0773-5","volume":"35","author":"P Montesinos","year":"2021","unstructured":"Montesinos P, et al. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2\/3 study. Leukemia. 2021;35(1):62\u201374.","journal-title":"Leukemia"},{"key":"1764_CR76","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00152","volume":"8","author":"CM Sch\u00fcrch","year":"2018","unstructured":"Sch\u00fcrch CM. Therapeutic antibodies for myeloid neoplasms\u2014current developments and future directions. Front Oncol. 2018;8: 152.","journal-title":"Front Oncol"},{"issue":"4","key":"1764_CR77","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, et al. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23(4):301\u201319.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1764_CR78","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","volume":"67","author":"C Spiess","year":"2015","unstructured":"Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67(2):95\u2013106.","journal-title":"Mol Immunol"},{"issue":"1","key":"1764_CR79","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","volume":"14","author":"Z Tian","year":"2021","unstructured":"Tian Z, et al. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol. 2021;14(1):75.","journal-title":"J Hematol Oncol"},{"key":"1764_CR80","volume":"13","author":"BC Taylor","year":"2022","unstructured":"Taylor BC, Balko JM. Mechanisms of MHC-I downregulation and role in immunotherapy response. Front Immunol. 2022;13: 844866.","journal-title":"Front Immunol"},{"issue":"6","key":"1764_CR81","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","volume":"100","author":"T Dreier","year":"2002","unstructured":"Dreier T, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer. 2002;100(6):690\u20137.","journal-title":"Int J Cancer"},{"key":"1764_CR82","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pharmthera.2017.12.002","volume":"185","author":"A Krishnamurthy","year":"2018","unstructured":"Krishnamurthy A, Jimeno A. Bispecific antibodies for cancer therapy: a review. Pharmacol Therapeut. 2018;185:122\u201334.","journal-title":"Pharmacol Therapeut"},{"issue":"1","key":"1764_CR83","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","volume":"13","author":"J Yu","year":"2020","unstructured":"Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol. 2020;13(1):45.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1764_CR84","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1073\/pnas.1812186116","volume":"116","author":"D Ha","year":"2019","unstructured":"Ha D, et al. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti\u2013CTLA-4 antibody. Proc Natl Acad Sci USA. 2019;116(2):609\u201318.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1764_CR85","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","volume":"32","author":"A Thakur","year":"2018","unstructured":"Thakur A, Huang M, Lum LG. Bispecific antibody based therapeutics: strengths and challenges. Blood Rev. 2018;32(4):339\u201347.","journal-title":"Blood Rev"},{"issue":"15_suppl","key":"1764_CR86","doi-asserted-by":"crossref","first-page":"e14000","DOI":"10.1200\/jco.2009.27.15_suppl.e14000","volume":"27","author":"S Parsons","year":"2009","unstructured":"Parsons S, et al. Clinical benefit of catumaxomab in malignant ascites in patient subpopulations in a pivotal phase II\/III trial. J Clin Oncol. 2009;27(15_suppl):e14000\u2013e14000.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1764_CR87","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1158\/1078-0432.CCR-06-2769","volume":"13","author":"A Burges","year":"2007","unstructured":"Burges A, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM\u00d7 anti-CD3 antibody: a phase I\/II study. Clin Cancer Res. 2007;13(13):3899\u2013905.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1764_CR88","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.leu.2402890","volume":"17","author":"A L\u00f6ffler","year":"2003","unstructured":"L\u00f6ffler A, et al. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct. Leukemia. 2003;17(5):900\u20139.","journal-title":"Leukemia"},{"issue":"3","key":"1764_CR89","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93(3):290\u20136.","journal-title":"Immunol Cell Biol"},{"issue":"6","key":"1764_CR90","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3390\/life11060465","volume":"11","author":"C Allen","year":"2021","unstructured":"Allen C, Zeidan AM, Bewersdorf JP. BiTEs, DARTS, BiKEs and TriKEs\u2014are antibody based therapies changing the future treatment of AML? Life. 2021;11(6):465.","journal-title":"Life"},{"key":"1764_CR91","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1182\/blood-2018-99-117150","volume":"132","author":"US Arvindam","year":"2018","unstructured":"Arvindam US, et al. CD16-IL15-CLEC12A trispecific killer engager (TriKE) drives NK cell expansion, activation, and antigen specific killing of cancer stem cells in acute myeloid leukemia. Blood. 2018;132:1454.","journal-title":"Blood"},{"issue":"17","key":"1764_CR92","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1182\/blood-2011-02-337691","volume":"117","author":"C Rader","year":"2011","unstructured":"Rader C. DARTs take aim at BiTEs. Blood. 2011;117(17):4403\u20134.","journal-title":"Blood"},{"key":"1764_CR93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-09033-7","volume":"22","author":"J Liu","year":"2022","unstructured":"Liu J, Tong J, Yang H. Targeting CD33 for acute myeloid leukemia therapy. BMC Cancer. 2022;22:1\u20137.","journal-title":"BMC Cancer"},{"issue":"12","key":"1764_CR94","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood-2016-10-696039","volume":"129","author":"DA Pollyea","year":"2017","unstructured":"Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 2017;129(12):1627\u201335.","journal-title":"Blood"},{"issue":"18","key":"1764_CR95","volume":"15","author":"MH Omer","year":"2023","unstructured":"Omer MH, et al. Bispecific antibodies in hematological malignancies: a scoping review. Cancers. 2023;15(18): 4550.","journal-title":"Cancers"},{"key":"1764_CR96","first-page":"317","volume-title":"Expert review of hematology","author":"RB Walter","year":"2014","unstructured":"Walter RB. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia. In: Expert review of hematology. Taylor & Francis; 2014. p. 317\u20139."},{"issue":"6","key":"1764_CR97","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1158\/1535-7163.MCT-13-0956","volume":"13","author":"M Friedrich","year":"2014","unstructured":"Friedrich M, et al. Preclinical characterization of AMG 330, a CD3\/CD33-bispecific t-cell\u2013engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014;13(6):1549\u201357.","journal-title":"Mol Cancer Ther"},{"key":"1764_CR98","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.7508","author":"F Ravandi","year":"2020","unstructured":"Ravandi F, et al. Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML). J Clin Oncol. 2020. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.7508.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1764_CR99","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","volume":"123","author":"C Krupka","year":"2014","unstructured":"Krupka C, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood. 2014;123(3):356\u201365.","journal-title":"Blood"},{"issue":"5","key":"1764_CR100","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/bloodadvances.2019001188","volume":"4","author":"P Nair-Gupta","year":"2020","unstructured":"Nair-Gupta P, et al. A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia. Blood Adv. 2020;4(5):906\u201319.","journal-title":"Blood Adv"},{"key":"1764_CR101","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1182\/blood-2018-99-118573","volume":"132","author":"LG Eissenberg","year":"2018","unstructured":"Eissenberg LG, et al. AMV564, a bivalent bispecific (2\u01682) CD33\/CD3 T-cell engager, is active and improves survival in a mouse model of acute myeloid leukemia. Blood. 2018;132:2727.","journal-title":"Blood"},{"key":"1764_CR102","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2018-99-111529","volume":"132","author":"P Westervelt","year":"2018","unstructured":"Westervelt P, et al. Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2x2) CD33\/CD3 T-cell engager, in patients with relapsed\/refractory acute myeloid leukemia (AML). Blood. 2018;132:1455.","journal-title":"Blood"},{"issue":"Supplement_1","key":"1764_CR103","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood-2019-129042","volume":"134","author":"P Westervelt","year":"2019","unstructured":"Westervelt P, et al. Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2:2) CD33\/CD3 T-cell engager, in patients with relapsed\/refractory acute myeloid leukemia (AML). Blood. 2019;134(Supplement_1):834\u2013834.","journal-title":"Blood"},{"key":"1764_CR104","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-134746","volume":"136","author":"F Ravandi","year":"2020","unstructured":"Ravandi F, et al. Complete responses in relapsed\/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of vibecotamab (XmAb14045), a CD123 x CD3 T cell-engaging bispecific antibody; initial results of a phase 1 study. Blood. 2020;136:4\u20135.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1764_CR105","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-134746","volume":"136","author":"F Ravandi","year":"2020","unstructured":"Ravandi F, et al. Complete responses in relapsed\/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of vibecotamab (XmAb14045), a CD123 x CD3 T cell-engaging bispecific antibody; initial results of a phase 1 study. Blood. 2020;136(Supplement 1):4\u20135.","journal-title":"Blood"},{"issue":"1","key":"1764_CR106","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2014-05-575704","volume":"127","author":"M Al-Hussaini","year":"2016","unstructured":"Al-Hussaini M, et al. Targeting CD123 in acute myeloid leukemia using a T-cell\u2013directed dual-affinity retargeting platform. Blood. 2016;127(1):122\u201331.","journal-title":"Blood"},{"issue":"289","key":"1764_CR107","doi-asserted-by":"crossref","first-page":"289ra82","DOI":"10.1126\/scitranslmed.aaa5693","volume":"7","author":"GR Chichili","year":"2015","unstructured":"Chichili GR, et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med. 2015;7(289):289ra82-289ra82.","journal-title":"Sci Transl Med"},{"key":"1764_CR108","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS7070","author":"N Vey","year":"2017","unstructured":"Vey N, et al. A phase I, first-in-human study of MGD006\/S80880 (CD123 x CD3 DART) in AML\/MDS. J Clin Oncol. 2017. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.TPS7070.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1764_CR109","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","volume":"137","author":"GL Uy","year":"2021","unstructured":"Uy GL, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021;137(6):751\u201362.","journal-title":"Blood"},{"key":"1764_CR110","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1182\/blood-2018-99-117085","volume":"132","author":"GL Uy","year":"2018","unstructured":"Uy GL, et al. Phase 1 cohort expansion of flotetuzumab, a CD123\u00d7 CD3 bispecific Dart\u00ae protein in patients with relapsed\/refractory acute myeloid leukemia (AML). Blood. 2018;132:764.","journal-title":"Blood"},{"key":"1764_CR111","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1182\/blood-2019-125966","volume":"134","author":"AH Wei","year":"2019","unstructured":"Wei AH, et al. A phase 1 study of Flotetuzumab, a CD123 x CD3 DART\u00ae protein, combined with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory acute myeloid leukemia. Blood. 2019;134:2662.","journal-title":"Blood"},{"issue":"4","key":"1764_CR112","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1158\/2326-6066.CIR-18-0748","volume":"7","author":"E Krawczyk","year":"2019","unstructured":"Krawczyk E, et al. T-cell activity against AML improved by dual-targeted T cells stimulated through T-cell and IL7 receptors. Cancer Immunol Res. 2019;7(4):683\u201392.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"1764_CR113","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","volume":"35","author":"US Arvindam","year":"2021","unstructured":"Arvindam US, et al. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. Leukemia. 2021;35(6):1586\u201396.","journal-title":"Leukemia"},{"issue":"5","key":"1764_CR114","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315\u201337.","journal-title":"Nat Rev Drug Discov"},{"key":"1764_CR115","doi-asserted-by":"crossref","first-page":"TPS7066","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS7066","volume":"35","author":"E Wang","year":"2017","unstructured":"Wang E, et al. CASCADE: a phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML). J Clin Oncol. 2017;35:TPS7066\u2013TPS7066.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1764_CR116","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1158\/1535-7163.MCT-17-1077","volume":"17","author":"Y Kovtun","year":"2018","unstructured":"Kovtun Y, et al. IMGN779, a novel CD33-targeting antibody-drug conjugate with DNA-alkylating activity, exhibits potent antitumor activity in models of AML. Mol Cancer Ther. 2018;17(6):1271\u20139.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1764_CR117","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","volume":"25","author":"NG Daver","year":"2024","unstructured":"Daver NG, et al. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody\u2013drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study. Lancet Oncol. 2024;25(3):388\u201399.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1764_CR118","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41375-025-02528-3","volume":"39","author":"SM Abedin","year":"2025","unstructured":"Abedin SM, et al. Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed\/refractory acute myeloid leukemia. Leukemia. 2025;39(4):837\u201343.","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"1764_CR119","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1182\/blood-2023-178802","volume":"142","author":"GJ Roboz","year":"2023","unstructured":"Roboz GJ, et al. Updated results from phase 1 study of targeted radiotherapy with lintuzumab-Ac225 in combination with Venetoclax in relapsed\/refractory AML. Blood. 2023;142(Supplement 1):1539\u20131539.","journal-title":"Blood"},{"issue":"5","key":"1764_CR120","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.clml.2018.02.017","volume":"18","author":"BC Medeiros","year":"2018","unstructured":"Medeiros BC, et al. A Phase I\/II Trial of the combination of azacitidine and gemtuzumab ozogamicin for treatment of relapsed acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2018;18(5):346-352.e5.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"1764_CR121","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","volume":"14","author":"H Liu","year":"2021","unstructured":"Liu H. Emerging agents and regimens for AML. J Hematol Oncol. 2021;14(1):49.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1764_CR122","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7\u201317.","journal-title":"Blood"},{"issue":"1","key":"1764_CR123","first-page":"1","volume":"3","author":"M Farrokhi","year":"2023","unstructured":"Farrokhi M, et al. Role of precision medicine and personalized medicine in the treatment of diseases. Kindle. 2023;3(1):1\u2013164.","journal-title":"Kindle"},{"issue":"15_suppl","key":"1764_CR124","doi-asserted-by":"crossref","first-page":"TPS7566","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS7566","volume":"38","author":"S Arain","year":"2020","unstructured":"Arain S, et al. Safety and efficacy of gemtuzumab ozogamicin and venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: a phase Ib study. J Clin Oncol. 2020;38(15_suppl):TPS7566\u2013TPS7566.","journal-title":"J Clin Oncol"},{"key":"1764_CR125","doi-asserted-by":"crossref","first-page":"S301","DOI":"10.1016\/S2152-2650(21)01716-X","volume":"21","author":"I Budaeva","year":"2021","unstructured":"Budaeva I, et al. AML-288: the combination of gemtuzumab ozogamicin and azacitidine in the treatment of relapsed and refractory AML. Clin Lymphoma Myeloma Leuk. 2021;21:S301.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"1764_CR126","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2021-150069","volume":"138","author":"C R\u00f6llig","year":"2021","unstructured":"R\u00f6llig C, et al. Gemtuzumab ozogamicin plus midostaurin in combination with standard intensive induction therapy in newly diagnosed AML: results from a phase-i study. Blood. 2021;138(Supplement 1):2324\u20132324.","journal-title":"Blood"},{"issue":"22","key":"1764_CR127","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.V128.22.590.590","volume":"128","author":"DL Bixby","year":"2016","unstructured":"Bixby DL, et al. Vadastuximab talirine monotherapy in older patients with treatment naive CD33-positive acute myeloid leukemia (AML). Blood. 2016;128(22):590\u2013590.","journal-title":"Blood"},{"issue":"11","key":"1764_CR128","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1309\/LMTDDRGLY374WSCQ","volume":"39","author":"MP Chao","year":"2008","unstructured":"Chao MP, Weissman IL, Park CY. Cancer stem cells: on the verge of clinical translation. Lab Med. 2008;39(11):679\u201386.","journal-title":"Lab Med"},{"key":"1764_CR129","unstructured":"Vyas, P.K., S.; Kelly, R.; Salim, R.; Lubowiecki, M.; Royston, D.; Johnson, H.; Roberts, C.; Chen, J.; Agoram, B.; et al., Initial Phase 1 Results of The First-In-Class Anti-Cd47 Antibody Hu5f9-G4 in Relapsed\/Refractory Acute Myeloid Leukemia Patients. 2018"},{"key":"1764_CR130","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1016\/S2152-2650(23)01083-2","volume":"23","author":"NG Daver","year":"2023","unstructured":"Daver NG, et al. AML-577 a phase III, randomized trial of magrolimab in combination with venetoclax and azacitidine in previously untreated patients with acute myeloid leukemia who are ineligible for intensive chemotherapy (ENHANCE-3). Clin Lymphoma Myeloma Leuk. 2023;23:S313\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"1764_CR131","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3390\/cancers13061423","volume":"13","author":"S Sendker","year":"2021","unstructured":"Sendker S, Reinhardt D, Niktoreh N. Redirecting the immune microenvironment in acute myeloid leukemia. Cancers (Basel). 2021;13(6):1423.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1764_CR132","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41375-019-0585-7","volume":"34","author":"N Tumino","year":"2020","unstructured":"Tumino N, et al. PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation. Leukemia. 2020;34(3):932\u20137.","journal-title":"Leukemia"},{"issue":"7768","key":"1764_CR133","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","volume":"572","author":"AM Paczulla","year":"2019","unstructured":"Paczulla AM, et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature. 2019;572(7768):254\u20139.","journal-title":"Nature"},{"issue":"3","key":"1764_CR134","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3324\/haematol.2019.240754","volume":"106","author":"AJ Ambinder","year":"2021","unstructured":"Ambinder AJ, Levis M. Potential targeting of FLT3 acute myeloid leukemia. Haematologica. 2021;106(3):671\u201381.","journal-title":"Haematologica"},{"issue":"Supplement_1","key":"1764_CR135","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2019-127977","volume":"134","author":"M Subklewe","year":"2019","unstructured":"Subklewe M, et al. Preliminary results from a phase 1 first-in-human study of AMG 673, a novel half-life extended (HLE) anti-CD33\/CD3 BiTE\u00ae (bispecific T-cell engager) in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML). Blood. 2019;134(Supplement_1):833\u2013833.","journal-title":"Blood"},{"issue":"1","key":"1764_CR136","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10238-025-01686-z","volume":"25","author":"AK Bishoyi","year":"2025","unstructured":"Bishoyi AK, et al. Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation. Clin Exp Med. 2025;25(1):166.","journal-title":"Clin Exp Med"},{"issue":"8","key":"1764_CR137","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2020006921","volume":"137","author":"S Willier","year":"2021","unstructured":"Willier S, et al. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. Blood. 2021;137(8):1037\u201349.","journal-title":"Blood"},{"issue":"1","key":"1764_CR138","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","volume":"13","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. Unveiling the potential of CLL-1: a promising target for AML therapy. Biomark Res. 2025;13(1):28.","journal-title":"Biomark Res"},{"issue":"6","key":"1764_CR139","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/leu.2011.372","volume":"26","author":"M Hofmann","year":"2012","unstructured":"Hofmann M, et al. Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia. Leukemia. 2012;26(6):1228\u201337.","journal-title":"Leukemia"},{"issue":"9","key":"1764_CR140","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3324\/haematol.2010.039743","volume":"96","author":"MJ Szczepanski","year":"2011","unstructured":"Szczepanski MJ, et al. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica. 2011;96(9):1302\u20139.","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"1764_CR141","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1182\/blood-2023-187498","volume":"142","author":"A Chin","year":"2023","unstructured":"Chin A, et al. Lintuzumab-Ac225, a CD33-directed antibody radiotherapy, targets AML in a mutation agnostic manner. Blood. 2023;142(Supplement 1):5750\u20135750.","journal-title":"Blood"},{"issue":"1","key":"1764_CR142","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/gene.2014.58","volume":"16","author":"A Baraga\u00f1o Raneros","year":"2015","unstructured":"Baraga\u00f1o Raneros A, et al. Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia. Genes Immun. 2015;16(1):71\u201382.","journal-title":"Genes Immun"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01764-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01764-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01764-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:53:49Z","timestamp":1764917629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01764-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":142,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1764"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01764-2","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"215"}}